Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
$0.60
$0.60
$0.59
$0.60
$31.81M-0.131 shsN/A
Immuneering Corporation stock logo
IMRX
Immuneering
$3.39
-5.6%
$2.00
$1.00
$3.87
$122.01M0.382.56 million shs908,546 shs
Nkarta, Inc. stock logo
NKTX
Nkarta
$1.76
+0.9%
$1.84
$1.31
$8.23
$124.54M0.71.04 million shs274,388 shs
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$0.54
+0.2%
$0.54
$0.31
$3.18
$124.98M1.239.06 million shs1.98 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
0.00%0.00%0.00%+31.90%+335.73%
Immuneering Corporation stock logo
IMRX
Immuneering
0.00%-3.97%+59.15%+151.11%+211.01%
Nkarta, Inc. stock logo
NKTX
Nkarta
0.00%+5.72%-7.63%+12.50%-66.12%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
0.00%-0.91%+1.13%-24.18%+66.20%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
4.0853 of 5 stars
3.34.00.00.04.25.00.6
Nkarta, Inc. stock logo
NKTX
Nkarta
2.0921 of 5 stars
3.61.00.00.01.91.70.6
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
2.7098 of 5 stars
3.34.00.00.02.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
0.00
N/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
2.60
Moderate Buy$13.25290.86% Upside
Nkarta, Inc. stock logo
NKTX
Nkarta
3.13
Buy$14.33716.71% Upside
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
2.67
Moderate Buy$4.50739.55% Upside

Current Analyst Ratings Breakdown

Latest HBPCF, NKTX, IMRX, and SGMO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$8.00 ➝ $10.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00
6/18/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/10/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$16.00 ➝ $14.00
6/5/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
5/15/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform
5/15/2025
Nkarta, Inc. stock logo
NKTX
Nkarta
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$11.00 ➝ $10.00
5/14/2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.00
5/7/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$25.00 ➝ $21.00
5/6/2025
Immuneering Corporation stock logo
IMRX
Immuneering
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
$320K381.27N/AN/A$1.33 per share2.55
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/A$5.78 per shareN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
$57.80M2.16N/AN/A$0.11 per share4.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
-$6.82M-$0.14N/AN/AN/AN/A-747.46%N/A
Immuneering Corporation stock logo
IMRX
Immuneering
-$61.04M-$1.96N/AN/AN/AN/A-119.22%-99.22%8/5/2025 (Estimated)
Nkarta, Inc. stock logo
NKTX
Nkarta
-$108.79M-$1.51N/AN/AN/AN/A-26.64%-21.62%8/12/2025 (Estimated)
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/5/2025 (Estimated)

Latest HBPCF, NKTX, IMRX, and SGMO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/16/2025Q3 2025
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A-$0.02N/A-$0.02N/AN/A
5/14/2025Q1 2025
Nkarta, Inc. stock logo
NKTX
Nkarta
-$0.44-$0.43+$0.01-$0.43N/AN/A
5/12/2025Q1 2025
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million
5/5/2025Q1 2025
Immuneering Corporation stock logo
IMRX
Immuneering
-$0.41-$0.42-$0.01-$0.42N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/AN/AN/AN/AN/A
Immuneering Corporation stock logo
IMRX
Immuneering
N/AN/AN/AN/AN/A
Nkarta, Inc. stock logo
NKTX
Nkarta
N/AN/AN/AN/AN/A
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A
0.42
0.42
Immuneering Corporation stock logo
IMRX
Immuneering
N/A
7.48
7.48
Nkarta, Inc. stock logo
NKTX
Nkarta
N/A
14.48
14.48
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
N/A
0.76
0.76

Institutional Ownership

CompanyInstitutional Ownership
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
N/A
Immuneering Corporation stock logo
IMRX
Immuneering
67.65%
Nkarta, Inc. stock logo
NKTX
Nkarta
80.54%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
56.93%

Insider Ownership

CompanyInsider Ownership
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
7.60%
Immuneering Corporation stock logo
IMRX
Immuneering
22.90%
Nkarta, Inc. stock logo
NKTX
Nkarta
8.40%
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
4.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Helix Biopharma Corp. stock logo
HBPCF
Helix Biopharma
953.02 million48.99 millionNot Optionable
Immuneering Corporation stock logo
IMRX
Immuneering
6035.99 million27.75 millionNot Optionable
Nkarta, Inc. stock logo
NKTX
Nkarta
14070.96 million65.00 millionOptionable
Sangamo Therapeutics, Inc. stock logo
SGMO
Sangamo Therapeutics
480233.17 million223.61 millionOptionable

Recent News About These Companies

Sangamo cues up Fabry gene therapy filing on STAAR data

New MarketBeat Followers Over Time

Media Sentiment Over Time

Helix Biopharma stock logo

Helix Biopharma OTCMKTS:HBPCF

$0.60 0.00 (0.00%)
As of 07/3/2025

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.

Immuneering stock logo

Immuneering NASDAQ:IMRX

$3.39 -0.20 (-5.57%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$3.38 -0.02 (-0.44%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Nkarta stock logo

Nkarta NASDAQ:NKTX

$1.76 +0.02 (+0.86%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$1.76 0.00 (0.00%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Sangamo Therapeutics stock logo

Sangamo Therapeutics NASDAQ:SGMO

$0.54 +0.00 (+0.19%)
Closing price 07/3/2025 03:56 PM Eastern
Extended Trading
$0.53 -0.01 (-1.31%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.